Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00237783 · ClinicalTrials.gov registry record · Phase 1
Safety of Dialysate Sodium Individualization in Hemodialysis Patients With Intradialytic Hypotension
A Phase 1 study, sponsored by Yale University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT00237783 is a Phase 1 study that was terminated before completion, run by Yale University. The registered enrollment target is 4 participants.
The verdict
NCT00237783, a Phase 1 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
Low blood pressure (hypotension) during dialysis afflicts approximately 25% of hemodialysis patients. In this pilot study, we will evaluate the safety and effects of individualizing the sodium concentration in the dialysate according to the patient's own plasma sodium levels. We hypothesize that patients will have less thirst and less weight gain during the intervention leading to easier fluid removal and less episodes of hypotension.
Interventions
- DRUG dialysate sodium (140 mmol/L)
- DRUG individualized dialysate sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2005-10 |
| Est. Completion | 2008-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00237783
The ClinicalTrials.gov registry entry for NCT00237783 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which dialysate sodium (140 mmol/L) is the first listed.
NCT00237783 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00237783 about?
NCT00237783 is a clinical study titled "Safety of Dialysate Sodium Individualization in Hemodialysis Patients With Intradialytic Hypotension". Low blood pressure (hypotension) during dialysis afflicts approximately 25% of hemodialysis patients. In this pilot study, we will evaluate the safety and effects of individualizing the sodium concentration in the dialysate according to the patient's own plasma sodium levels. We hypothesize that pat...
What is the current status of trial NCT00237783?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2005-10. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00237783?
The interventions under investigation include: dialysate sodium (140 mmol/L) (DRUG), individualized dialysate sodium (DRUG).
Who is sponsoring clinical trial NCT00237783?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.